Objectives: To review the current literature about prostate-sparing radical cystectomy (PSRC) and its potential for management of a selected population of patients with bladder cancer. Materials and Methods: The PubMed, EMBASE and Scopus databases were searched for the key words ‘prostate', ‘sparing' and ‘cystectomy' between 1984 and 2012. Articles in English, French and German were considered relevant for review. Institutional experience with this procedure was also included. Results: PSRC remains a controversial procedure for the treatment of patients harboring bladder carcinoma, mainly due to insufficient knowledge of clear indications and/or contraindications. Experience with PSRC is still limited to very few referral centers and there is a lack of large series with long-term outcomes. The potential for excellent functional outcomes must be carefully balanced against inconsistent oncological results. Conclusions: PSRC may become an option for carefully selected and extensively informed patients. Suggestions for possible indications and contraindications are presented.

Keywords:
Bladder cancer, Prostate, Cystectomy, Continence, Erectile dysfunction, Ejaculation, Sparing
1.
Babjuk M, Oosterlinck W, Sylvester R, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
2.
Stenzl A, Cowan NC, De Santis M, et al: Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-1018.
3.
Hautmann RE, Volkmer BG, Gust K: Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol 2009;27:347-351.
4.
van den Bosch S, Alfred Witjes J: Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011;60:493-500.
5.
Jäger W, Thomas C, Haag S, et al: Early vs delayed radical cystectomy for ‘high-risk' carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival. BJU Int 2011;108:E284-E288.
6.
Huguet J, Gaya JM, Sabate S, Palou J, Villavicencio H: Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy. Actas Urol Esp 2010;34:63-70.
7.
Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED: Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 2009;27:155-159.
8.
Canter D, Egleston B, Wong YN, et al: Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis. Urol Oncol DOI: 10.1016/j.urolonc.2011.07.009.
9.
Morganstern BA, Bochner B, Dalbagni G, Shabsigh A, Rapkin B: The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery. Health Qual Life Outcomes 2011;9:10.
10.
Daneshmand S, Bartsch G: Improving selection of appropriate urinary diversion following radical cystectomy for bladder cancer. Expert Rev Anticancer Ther 2011;11:941-948.
11.
Stenzl A, Sherif H, Kuczyk M: Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. Int Braz J Urol 2010;36:537-547.
12.
Girgin C, Oder M, Sahin MO, et al: Erection- and ejaculation-preserving cystectomy with orthotopic urinary diversion: is it feasible? J Androl 2006;27:263-267.
13.
Klotz L, Pinthus J: The case for prostate capsule-sparing radical cystectomy in selected patients. Can Urol Assoc J 2009;3(6 suppl 4): S215-S219.
14.
Puppo P, Introini C, Bertolotto F, Naselli A: Potency preserving cystectomy with intrafascial prostatectomy for high risk superficial bladder cancer. J Urol 2008;179:1727-1732.
15.
Rozet F, Harmon J, Arroyo C, Cathelineau X, Barret E, Vallancien G: Benefits of laparoscopic prostate-sparing radical cystectomy. Expert Rev Anticancer Ther 2006;6:21-26.
16.
Salem HK: Preservation of ejaculatory and erectile function after radical cystectomy for urothelial malignancy. J Egypt Natl Canc Inst 2005;17:239-244.
17.
Nieuwenhuijzen JA, Meinhardt W, Horenblas S: Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol 2008;179(5 suppl):S35-S38.
18.
Hautmann RE, Hautmann SH, Hautmann O: Complications associated with urinary diversion. Nat Rev Urol 2011;8:667-677.
19.
Liedberg F, Holmberg E, Holmang S, et al: Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey. Scand J Urol Nephrol 2012;46:14-18.
20.
Hautmann RE, de Petriconi RC, Volkmer BG: 25 years of experience with 1,000 neobladders: long-term complications. J Urol 2011;185:2207-2212.
21.
Kessler TM, Burkhard FC, Studer UE: Clinical indications and outcomes with nerve-sparing cystectomy in patients with bladder cancer. Urol Clin North Am 2005;32:165-175.
22.
Lane BR, Finelli A, Moinzadeh A, et al: Nerve-sparing laparoscopic radical cystectomy: technique and initial outcomes. Urology 2006;68:778-783.
23.
Ong CH, Schmitt M, Thalmann GN, Studer UE: Individualized seminal vesicle sparing cystoprostatectomy combined with ileal orthotopic bladder substitution achieves good functional results. J Urol 2010;183:1337-1341.
24.
Vallancien G, Abou El Fettouh H, Cathelineau X, Baumert H, Fromont G, Guillonneau B: Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 2002;168:2413-2417.
25.
Smith AB, Raynor M, Amling CL, et al: Multi-institutional analysis of robotic radical cystectomy for bladder cancer: perioperative outcomes and complications in 227 patients. J Laparoendosc Adv Surg Tech A 2012;22:17-21.
26.
Wan J, Grossman HB: Bladder carcinoma in patients age 40 years or younger. Cancer 1989;64:178-181.
27.
Abdelsalam YM, Mokhtar AA, Kurkar AA, Saleh MA, el-Ganainy EO: Defining patient selection for prostate-sparing cystectomy in squamous cell carcinoma of the urinary bladder associated with bilharziasis: an overview of 236 patients. Urology 2011;78:1351-1354.
28.
Arce J, Gaya JM, Huguet J, Rodriguez O, Palou J, Villavicencio H: Can we identify those patients who will benefit from prostate-sparing surgery? Predictive factors for invasive prostatic involvement by transitional cell carcinoma. Can J Urol 2011;18:5529-5536.
29.
Hautmann RE, Stein JP: Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am 2005;32:177-185.
30.
Rozet F, Lesur G, Cathelineau X, et al: Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol 2008;179:2170-2174.
31.
Salem HK: Radical cystectomy with preservation of sexual function and fertility in patients with transitional cell carcinoma of the bladder: new technique. Int J Urol 2007;14:294-298.
32.
Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1,100 patients. Eur Urol 2012;61:1039-1047.
33.
Terrone C, Porpiglia F, Cracco C, et al: Supra-ampullar cystectomy and ileal neobladder. Eur Urol 2006;50:1223-1233.
34.
de Vries RR, Nieuwenhuijzen JA, van Tinteren H, et al: Prostate-sparing cystectomy: long-term oncological results. BJU Int 2009;104:1239-1243.
35.
Simone G, Papalia R, Leonardo C, et al: Prostatic capsule and seminal vesicle-sparing cystectomy: improved functional results, inferior oncologic outcome. Urology 2008;72:162-166.
36.
Saidi A, Nahon O, Daniel L, Lay F, Lechevallier E, Coulange C: Prostate-sparing cystectomy: long-term functional and oncological results in a series of 25 cases. Prog Urol 2004;14:172-177.
37.
Botto H, Sebe P, Molinie V, Herve JM, Yonneau L, Lebret T: Prostatic capsule- and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patients. BJU Int 2004;94:1021-1025.
38.
Stein JP, Hautmann RE, Penson D, Skinner DG: Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. Urol Oncol 2009;27:466-472.
39.
Tabibi A, Simforoosh N, Parvin M, et al: Predictive factors for prostatic involvement by transitional cell carcinoma of the bladder. Urol J 2011;8:43-47.
40.
Kefer JC, Campbell SC: Current status of prostate-sparing cystectomy. Urol Oncol 2008;26:486-493.
41.
Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA Jr, Shappell SB: Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol 2008;179(5 suppl):S27-S32.
42.
Ayyathurai R, Gomez P, Luongo T, Soloway MS, Manoharan M: Prostatic involvement by urothelial carcinoma of the bladder: clinicopathological features and outcome after radical cystectomy. BJU Int 2007;100:1021-1025.
43.
Kotb A, Aprikian AG: Is sparing the prostate still considered radical cystectomy? The case against prostate-sparing cystectomy for bladder cancer. Can Urol Assoc J 2009;3(6 suppl 4): S220-S222.
44.
Pettus JA, Al-Ahmadie H, Barocas DA, et al: Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol 2008;53:370-375.
45.
Richards KA, Parks GE, Badlani GH, Kader AK, Hemal AK, Pettus JA: Developing selection criteria for prostate-sparing cystectomy: a review of cystoprostatectomy specimens. Urology 2010;75:1116-1120.
46.
Nixon RG, Chang SS, Lafleur BJ, Smith JJ, Cookson MS: Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 2002;167:502-505.
47.
Miranda-Sousa AJ, Davila HH, Lockhart JL, Ordorica RC, Carrion RE: Sexual function after surgery for prostate or bladder cancer. Cancer Control 2006;13:179-187.
48.
Donat SM, Genega EM, Herr HW, Reuter VE: Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J Urol 2001;165:1117-1120.
49.
Huguet J: Management of the male urethra before and after cystectomy: from the prophylactic urethrectomy to the intraoperative frozen section biopsy of the urethral margin. Actas Urol Esp 2011;35:552-558.
50.
Gakis G, Schilling D, Bedke J, Sievert KD, Stenzl A: Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery. BJU Int 2010;105:468-471.
51.
Davila HH, Weber T, Burday D, et al: Total or partial prostate sparing cystectomy for invasive bladder cancer: long-term implications on erectile function. BJU Int 2007;100:1026-1029.
52.
Muto G, Bardari F, D'Urso L, Giona C: Seminal sparing cystectomy and ileocapsuloplasty: long-term followup results. J Urol 2004;172:76-80.
53.
Thomas C, Wiesner C, Melchior S, Gillitzer R, Schmidt F, Thuroff JW: Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer. J Urol 2008;180:1938-1941.
54.
Wunderlich H, Wolf M, Reichelt O, Frober R, Schubert J: Radical cystectomy with ultrasound-guided partial prostatectomy for bladder cancer: a complication-preventing concept. Urology 2006;68:554-559.
55.
Spitz A, Stein JP, Lieskovsky G, Skinner DG: Orthotopic urinary diversion with preservation of erectile and ejaculatory function in men requiring radical cystectomy for nonurothelial malignancy: a new technique. J Urol 1999;161:1761-1764.
56.
Arroyo C, Andrews H, Rozet F, Cathelineau X, Vallancien G: Laparoscopic prostate-sparing radical cystectomy: the Montsouris technique and preliminary results. J Endourol 2005;19:424-428.
57.
Pinthus JH, Nam RK, Klotz LH: Prostate sparing radical cystectomy - not for all, but an option for some. Can J Urol 2006;13(suppl 1):81-87.
58.
Heidenreich A, Porres D, Pfister D: Treatment of bladder cancer. Value of radical prostate-sparing cystectomy. Urologe A 2012;51:813-819.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.